Efficacy and Safety of Jianpi Jieyu Decoction for Patients with Mild-to-Moderate Depression of Xin (Heart)-Pi (Spleen) Deficiency Syndrome: A Multi-centre Randomized Controlled Study.
10.1007/s11655-022-3685-6
- Author:
Xu CHEN
1
;
Jiu-Xi CHEN
2
;
Xue-Yan HAN
3
;
Yang ZHAO
4
;
Jing CAO
2
;
Xiu-Zhen JIAO
5
;
Hong-Mei LIU
2
;
Chun-Li GUO
2
;
Shuo MENG
6
;
Shuai LIANG
7
;
Jiang-Xia QI
2
;
Dong CHEN
2
;
Ming-Xia LI
5
;
Yun-Xia JIAO
5
;
Ting-Ting WANG
5
;
Xia HONG
8
Author Information
1. Xiyuan Clinical Medical College, Beijing University of Chinese Medicine, Beijing, 100091, China.
2. Department of Encephalopathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
3. First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
4. Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
5. Department of Encephalopathy, Botou Traditional Chinese Medicine Hospital of Hebei Province, Botou, 062150, China.
6. Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
7. Department of Nephrology, Pinggu Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing, 101299, China.
8. Department of Encephalopathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. 970236538@qq.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Jianpi Jieyu Decoction;
Xin (Heart)-Pi (Spleen) deficiency syndrome;
depression;
efficacy;
safety
- MeSH:
Humans;
Paroxetine/adverse effects*;
Spleen;
Anxiety;
Syndrome;
Medicine, Chinese Traditional;
Treatment Outcome;
Double-Blind Method
- From:
Chinese journal of integrative medicine
2023;29(4):299-307
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of Jianpi Jieyu Decoction (JJD) for treating patients with mild-to-moderate depression of Xin (Heart)-Pi (Spleen) deficiency (XPD) syndrome.
METHODS:In this multi-center, randomized, controlled study, 140 patients with mild-to-moderate depression of XPD syndrome were included from Xiyuan Hospital of China Academy of Chinese Medical Sciences and Botou Hospital of Traditional Chinese Medicine from December 2017 to December 2019. They were randomly divided into JJD group and paroxetine group by using a random number table, with 70 cases in each group. The patients in the JJD group were given JJD one dose per day (twice daily at morning and evening, 100 mL each time), and the patients in the paroxetine group were given paroxetine (10 mg/d in week 1; 20 mg/d in weeks 2-6), both orally administration for a total of 6 weeks. The primary outcome was the change of 17-item Hamilton Depression Rating Scale (HAMD-17) score at week 6 from baseline. The secondary outcomes included the Hamilton Anxiety Scale (HAMA) score, Traditional Chinese Medicine Symptom Scale (TCMSS), and Clinlcal Global Impression (CGI) scores at the 2nd, 4th, and 6th weekends of treatment, HAMD-17 response (defined as a reduction in score of >50%) and HAMD-17 remission (defined as a score of ⩽7) at the end of the 6th week of treatment. Adverse events (AEs) were also recorded.
RESULTS:From baseline to week 6, the HAMD-17 scores decreased 10.2 ± 4.0 and 9.1 ± 4.9 points in the JJD and paroxetine groups, respectively (P=0.689). The HAMD-17 response occurred in 60% of patients in the JJD group and in 50% of those in the paroxetine group (P=0.292); HAMD-17 remission occurred in 45.7% and 30% of patients, respectively (P=0.128). The differences of CGI scores at the 6th week were not statistically significant (P>0.05). There were significant differences in HAMD-17 scores between the two groups at 2nd and 4th week (P=0.001 and P=0.014). The HAMA scores declined 8.1 ± 3.0 and 6.9 ± 4.3 points from baseline to week 6 in the JJD and paroxetine groups, respectively (P=0.905 between groups). At 4th week of treatment, there was a significant difference in HAMA between the two groups (P=0.037). TCMSS decreased 11.4 ± 5.1, and 10.1 ± 6.8 points in the JJD and paroxetine groups, respectively (P=0.080 between groups). At the 6th week, the incidence of AEs in the JJD group was significantly lower than that in the paroxetine group (7.14% vs. 22.86%, P<0.05).
CONCLUSION:Compared with paroxetine, JJD was associated with a significantly lower incidence of AEs in patients with mild-to-moderate depression of XPD syndrome, with no difference in efficacy at 6 weeks. (Trial registration No. ChiCTR2000040922).
